SCHEMBL4970944

SCHEMBL4970944

O=C1CCc2cc(-c3ccccc3)ccc2C1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.67
CYP11B1 P15538 3/20 0.67
CYP11B2 P19099 3/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2C9 P11712 2/20 0.67
CYP2C19 P33261 2/20 0.67
CYP2A6 P11509 1/20 0.59
TDP2 O95551 5/20 0.51
PARP10 Q53GL7 1/20 0.46
PARP11 Q9NR21 1/20 0.46
TYRO3 Q06418 2/20 0.45
NTRK2 Q16620 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
DYRK1B Q9Y463 2/20 0.45
HSD17B3 P37058 2/20 0.43
SRD5A1 P18405 1/20 0.41
CFTR P13569 1/20 0.41
GOPC Q9HD26 1/20 0.41
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27806355 0.93 CYP2A6 (0.59) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL5161609 0.86 CYP1A2 (0.56) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL4971962 0.84 CYP1A2 (0.56) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL27843779 0.83 CYP11B1 (0.49) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL27843802 0.83 CYP11B1 (0.49) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL6253369 0.82 HSD17B3 (0.51) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL4893296 0.81 TDP2 (0.57) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
Ammonia Solution, Strong SCHEMBL4888955 0.80 HSD17B3 (0.50) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL4971011 0.80 CYP11B1 (0.70) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9
SCHEMBL4972557 0.80 CYP1A2 (0.52) CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101768086-A Amino methanol derivant and salt compound thereof as well as synthesizing method and medical application thereof BEIJING FUKA BIOTECHNOLOGY CO 2010-07-07 CN disclosed
WO-2008118790-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-02 WO disclosed
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC40A1, HAMP CYP1A2 78/4885CYP11B1 12/4885CYP11B2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.